Vitamin D and cancer

被引:94
作者
Mehta, RG [1 ]
Mehta, RR [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL 60612 USA
关键词
vitamin D; analogs of vitamin D; VDR; carcinogenesis; metabolism; mechanism of action;
D O I
10.1016/S0955-2863(02)00183-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vitamin D, a steroid hormone and exerts its biological effects through its active metabolite 1alpha, 25 dihydroxyvitamin D3 [1,25(OH)2D3]. Like steroid hormones, 1,25(OH)2D3 is efficacious at very low concentrations and serves as a ligand for vitamin D receptors (VDR), associating with VDR very high affinity. Despite its potent property as a differentiating agent, its use in the clinical practice is hampered by the induction of hypercalcemia at a concentration required to suppress cancer cell proliferation. Therefore nearly 400 structural analogs of vitamin D3 have been synthesized and evaluated for their efficacy and toxicity. Among these analogs, relatively less toxic but highly efficacious analogs, EB1089, RO24-5531, 1alpha-hydroxyvitamin D5 and a few others have been evaluated in a preclinical toxicity and in Phase I clinical trials for dose tolerance in advanced cancer patients. Clinical trials using vitamin D analogs for prevention or therapy of cancer patients are still in their infancy. Vitamin D mediates its action by two independent pathways. Genomic pathway involves nuclear VDR and induces biological effects by interactions with hormone response elements and modulation of differential gene expressions. Evidence also suggests that vitamin D analogs also interact with steroid hormone(s) inducible genes. The non-genomic pathway is characterized by rapid actions of vitamin D. It involves interactions with membrane-VDR interactions and its interactions with protein kinase C and by altering intracellular calcium channels. Thus, the development of nontoxic analogs of vitamin D analogs and understanding of their molecular mechanism(s) of action are of significant importance in the prevention and treatment of cancer by vitamin D. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:252 / 264
页数:13
相关论文
共 81 条
[41]   Experimental basis for the prevention of breast cancer [J].
Mehta, RG .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (10) :1275-1282
[42]   Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1 alpha-hydroxyvitamin D-5 [J].
Mehta, RG ;
Moriarty, RM ;
Mehta, RR ;
Penmasta, R ;
Lazzaro, G ;
Constantinou, A ;
Guo, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :212-218
[43]   GROWTH AND METASTASIS OF HUMAN BREAST CARCINOMAS WITH MATRIGEL IN ATHYMIC MICE [J].
MEHTA, RR ;
GRAVES, JM ;
HART, GD ;
SHILKAITIS, A ;
DASGUPTA, TK .
BREAST CANCER RESEARCH AND TREATMENT, 1993, 25 (01) :65-71
[44]  
Mehta RR, 2000, INT J ONCOL, V16, P65
[45]  
Mellanby E, 1919, LANCET, V1, P407
[46]  
Mils V, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P87
[47]   An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene [J].
Mitchell, SH ;
Murtha, PE ;
Zhang, SB ;
Zhu, W ;
Young, CYF .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2000, 168 (1-2) :89-99
[48]  
Moon Richard C., 1994, P573
[49]   SYNTHESIS OF VITAMIN-D5 - ITS BIOLOGICAL-ACTIVITY RELATIVE TO VITAMIN-D3 AND VITAMIN-D2 [J].
NAPOLI, JL ;
FIVIZZANI, MA ;
SCHNOES, HK ;
DELUCA, HF .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1979, 197 (01) :119-125
[50]  
NEMERE I, 1987, J BONE MINER RES, V2, P99